Latest news with #Masimo
Yahoo
11-07-2025
- Business
- Yahoo
Masimo, STAAR Surgical, Teleflex, Omnicell, and Integra LifeSciences Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Patient Monitoring company Masimo (NASDAQ:MASI) fell 3.1%. Is now the time to buy Masimo? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company STAAR Surgical (NASDAQ:STAA) fell 3.4%. Is now the time to buy STAAR Surgical? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Teleflex (NYSE:TFX) fell 3%. Is now the time to buy Teleflex? Access our full analysis report here, it's free. Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) fell 3.7%. Is now the time to buy Omnicell? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Integra LifeSciences (NASDAQ:IART) fell 4.6%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it's free. Integra LifeSciences's shares are very volatile and have had 26 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Integra LifeSciences is down 45.1% since the beginning of the year, and at $12.63 per share, it is trading 60.2% below its 52-week high of $31.74 from July 2024. Investors who bought $1,000 worth of Integra LifeSciences's shares 5 years ago would now be looking at an investment worth $272.55. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Business
- Yahoo
BD appoints Bilal Muhsin as president of new connected care group
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Bilal Muhsin New role: President of connected care, BD Previous role: Chief operating officer, Masimo BD said Monday that it has named Bilal Muhsin as president of its new connected care segment. The hire is effective as of July 2. The company is creating the segment as part of the restructuring it announced in February. Connected care will house BD's medication management and advanced patient monitoring devices, giving it control of products including the Pyxis line of automated dispensing systems and Alaris infusion pumps. Muhsin has joined BD to help set up the new segment. Reporting to BD CEO Tom Polen, the executive will lead strategy development to support the transition to the revised structure over the next several months. Polen said in a statement that Muhsin's 'extensive and deep knowledge of connected care technologies, software and informatics strategies' will help BD as it advances its connected care strategy. Muhsin developed the knowledge during his 25 years at Masimo, a medtech company that built a portfolio of patient monitoring devices around pulse oximeter technology. Masimo told investors last month that Muhsin was resigning as chief operating officer to pursue other opportunities. The company, which did not replace Muhsin when he left on July 1, disclosed the change alongside an overhaul of its commercial leadership. At BD, Muhsin will take over a connected care business that the company has grown through deals such as the $1.53 billion buyout of Parata Systems and $93 million acquisition of Medkeeper. The pharmacy robotics business that BD has built through the recent acquisitions sits alongside the Pyxis franchise that the company added to its portfolio through the $12.2 billion takeover of Carefusion in 2015. The Pyxis business received a warning letter from the Food and Drug Administration last year and is now entering an important period. BD recently began shipping a new Pyxis device, Polen said at a Goldman Sachs event last month. The CEO said the launch could cause market share to 'shift incrementally' and presents an opportunity to charge a price premium. Recommended Reading BD plans split from life science business to fuel medtech investment
Yahoo
09-07-2025
- Business
- Yahoo
Joe Kiani is back: After being ousted from Masimo the billionaire has returned as CEO of Like Minded Labs
In today's CEO Daily: Diane Brady talks to Joe Kiani, late of Masimo, who has just become the CEO of Like Minded Labs. The big story: Trump and his tariffs, again. The markets: Shrugging off the president's latest trade plan. Analyst notes from Deutsche Bank on The Fed, on consumer shopping, and Goldman Sachs on the S&P 500. Plus: All the news and watercooler chat from Fortune. Good morning. Joe Kiani was crushed last September when shareholder activist Quentin Koffey of Politan Capital succeeded in his two-year battle to push Kiani off the board of Masimo, a med-tech company that he founded and built over 36 years. When Kiani quit as CEO, I presumed the billionaire entrepreneur would focus on pursuits away from the public eye. Not so. Kiani will this morning be named CEO of Like Minded Labs, a small company that develops innovative video technologies for the entertainment industry, among other things. Kiani co-founded it after buying a Quebec-based company that created the core technology that he says will now be the foundation for some major product launches. He will continue to work his other ventures, but this marks his first return to being CEO—albeit at a company with three dozen people or roughly 1% the staff of Masimo. Why step back into the spotlight after such a bruising public battle? 'I spent a few months thinking about that,' he told me yesterday. 'I just want to build products. I have these ideas in my head of how I see the world. I don't need the money or the credit. I'm just wired to do this … and it entails advanced signal processing, which I know.' (Masimo's core product is a pulse oximeter that Kiani invented.) Kiani does have some advantages this time around. One is Bob Chapek, the former Disney CEO who supported him as a board member of Masimo and is joining the new board. He also has resources, a track record, and majority ownership, noting 'I'm not going to make the same mistake twice.' Any lessons to share from the Masimo battle? 'Give it your best. I've never seen an activist come in and do a good thing for the company,' he said. Masimo shareholders may disagree as the stock price is up about 45% since Kiani resigned on Sept. 19—though it dropped amid the proxy battle and is down since the start of the year. 'I don't regret that I tried my best.'Contact CEO Daily via Diane Brady at This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-07-2025
- Health
- Yahoo
Pulse Oximeter Market to Hit $7.03 Billion by 2032--Redefining Respiratory Monitoring in Modern Healthcare
DELRAY BEACH, Fla., July 9, 2025 /PRNewswire/ -- What's powering an $7.03 billion global pulse oximeter opportunity? The global pulse oximeters market, valued at US$3.59 billion in 2024, stood at US$3.92 billion in 2025 and is projected to advance at a resilient CAGR of 8.7% from 2025 to 2032, culminating in a forecasted valuation of US$7.03 billion by the end of the period. This growth is underpinned by the global surge in respiratory disorders, expanding elderly population, rising surgical volumes, and increased demand for non-invasive, real-time patient monitoring. For healthcare leaders and investors, pulse oximetry is no longer a peripheral tool—it's a frontline monitoring solution vital to quality care delivery and long-term cost containment. Download PDF Brochure: Why is pulse oximetry emerging as a clinical cornerstone in respiratory care? Whether in high-acuity ICUs or home care settings, pulse oximeters provide essential oxygen saturation and heart rate insights. As chronic conditions like COPD and asthma rise globally, portable, wearable, and connected pulse oximeters are enabling continuous, actionable monitoring. These innovations reduce emergency visits, enable timely interventions, and align care pathways with value-based healthcare models—turning real-time monitoring into measurable outcomes. What real-world problems do pulse oximeters solve? From silent hypoxemia in respiratory diseases to complications from delayed diagnosis, pulse oximeters offer a proactive solution for hospitals, payors, and clinicians. They support continuous SpO₂ and pulse rate monitoring in outpatient, inpatient, and home environments. The newest generation of Bluetooth and AI-enhanced devices allow seamless integration with EHRs, enabling better clinical decisions, fewer readmissions, and a more connected care ecosystem. Where are the most investable growth regions? Emerging economies—especially India, China, Brazil, and Southeast Asia—are becoming high-growth hotspots. These regions benefit from favorable demographics, increased government investment in health infrastructure, and growing awareness of chronic respiratory conditions. Additionally, global manufacturers are leveraging these markets for both cost-effective production and sales, driven by less stringent regulations and local demand for low-cost, reliable monitoring tools. Request Sample Pages: Who's leading the pulse oximeter market—and who's gaining ground? Medtronic holds the largest share (25–29%) with an extensive product lineup and global footprint. Masimo continues to lead with its proprietary SET® technology, dominating hospital contracts and remote monitoring integrations. Philips, Nonin Medical, Nihon Kohden, and GE Healthcare are expanding product portfolios in wearable and clinical-grade segments. New entrants and regional players like Lepu Medical and Contec are gaining traction through aggressive pricing and regional expansion strategies. What are the market's pain points—and how do you unlock faster adoption? Despite robust demand, adoption of pulse oximeters—especially OTC and low-cost models—is challenged by regulatory scrutiny and accuracy concerns. FDA advisories highlight the limitations of consumer-grade devices. To gain long-term trust, companies must invest in clinical validation, provider education, and compliance with evolving standards. Executive buy-in depends on clear ROI modeling, training programs, and proof of performance under real-world conditions. So, what should healthcare executives and investors really be asking?Not "Do we need pulse oximetry?"—but: How can we embed pulse oximeters into our RPM (Remote Patient Monitoring) strategy? Are our care models aligned with scalable, data-integrated oxygen monitoring solutions? Can we validate device accuracy and demonstrate clinical ROI to stakeholders? Which manufacturing and distribution partners can accelerate our presence in emerging economies? Final Thought: Real-Time Monitoring. Real-World Impact. In today's outcome-driven landscape, pulse oximeters offer more than vital sign tracking—they enable proactive, connected, and cost-effective care. Their role in surgical recovery, chronic disease management, and decentralized trials makes them indispensable to the future of healthcare delivery. The pulse oximeter market is no longer in observation mode—it's in execution. Precision monitoring is the new frontline. The ROI is real. The market is ready. For more information, Inquire Now! Related Reports: Surgical Sutures Market Wound Care Market Biosurgery Market Knee Replacement Surgery Market Surgical Suction Instruments Market Get access to the latest updates on Top Companies in Pulse Oximeter and Pulse Oximeter Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Globe and Mail
08-07-2025
- Health
- Globe and Mail
Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation
Masimo (NASDAQ: MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: Masimo is a member of the American Heart Association's Innovators' Network The Innovators' Network is a health care technology consortium that connects entrepreneurs, providers, researchers, and payers. Innovators' Network members also have the opportunity to access the Association's digital evidence-based scientific guidelines and clinical recommendations as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including building models for clinical outcome studies (which lowers the significant cost of developing those studies independently), helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers. 'The Center aims to advance the rapid, efficient, and effective development of healthcare technology,' said Robert A. Harrington, M.D., FAHA, volunteer past president of the American Heart Association (2019-2020), chair of the American Heart Association's Health Tech Advisory Group for the Center and the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. 'Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.' Daniel Cantillon, MD, Chief Medical Officer at Masimo, commented, 'We're proud to join the American Heart Association Innovators' Network to ensure that our next generation of cardiovascular and brain health monitoring solutions address critical unmet needs – especially for the most vulnerable patients in historically underserved communities.' @Masimo | #Masimo About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding Masimo joining the American Heart Association Center for Health Technology & Innovation; strategic and other potential benefits of becoming a member of the Center for Health Technology & Innovation; Masimo's development of its existing products or any new product solutions; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'on-going,' 'opportunity,' 'plan,' 'potential,' 'predicts,' 'forecast,' 'project,' 'seek,' 'should,' 'will,' or 'would,' the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: our ability to effectively protect our intellectual property from competitors; our ability to allocate sufficient time resources toward our relationship with the Center for Health Technology & Innovation; obtaining regulatory approval of our current and future products and technologies; and other factors discussed in the 'Risk Factors' section of our most recent periodic reports filed with the Securities and Exchange Commission ('SEC'), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the 'Risk Factors' contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
